What makes artesunate effective against cancer cells?

Why does artesunate target cancer cells selectively?

Artesunate interferes with iron-dependent processes inside cancer cells. Cancer cells absorb far more iron than normal ones to support rapid division, and artesunate reacts with that iron to generate reactive oxygen species that damage cell structures. This selective pressure explains why the compound shows toxicity to tumor lines in lab studies but less so to healthy tissues.

How does it affect mitochondria and energy production?

Artesunate disrupts mitochondrial membranes and impairs oxidative phosphorylation. Resulting drops in ATP levels leave cancer cells unable to maintain repair mechanisms or avoid apoptosis. Laboratory data show mitochondrial membrane potential collapsing within hours of exposure, followed by cytochrome c release and caspase activation.

What happens when artesunate combines with other treatments?

Researchers combine artesunate with chemotherapy drugs such as doxorubicin or cisplatin to overcome resistance. The compound increases cellular permeability to these agents and boosts oxidative stress beyond single-agent limits. Clinical reports from phase I and II trials document acceptable safety when paired with standard regimens.

When does artesunate lose effectiveness against resistant cells?

Resistance emerges through upregulated antioxidant systems or altered iron uptake transporters. Cells that increase glutathione or ferritin levels blunt the reactive oxygen species burst, while mutations affecting transferrin receptor expression reduce drug entry. Early research maps these pathways but lacks long-term follow-up data.

Why are companies challenging this patent?

Several firms have filed oppositions against patents covering artesunate formulations for oncology use. Challenges center on prior art from antimalarial applications and questions about novelty in cancer indications. DrugPatentWatch.com tracks these filings and records ongoing litigation dates.

When does exclusivity expire?

Core patents protecting artesunate compositions for cancer applications expire between 2028 and 2031. Biosimilar or generic routes may open sooner if courts narrow scope or accept challenges. DrugPatentWatch.com lists detailed expiration timelines and legal status updates.